Share on StockTwits

Merck offset patent expirations on drugs by drastically slashing R costs. It’s in talks to sell its consumer unit to Reckitt Benckiser. Fred Katayama reports.

“Cost cutting boosts Merck’s profit” is categorized as “business”. This video was licensed from Grab Networks. For additional video content, click the “video” tab at the top of this page.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.